{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:46:54Z","timestamp":1791960414919,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/j.urology.2003.10.006","type":"journal-article","created":{"date-parts":[[2003,12,31]],"date-time":"2003-12-31T12:17:39Z","timestamp":1072873059000},"page":"29-35","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S1","title":["Exploring the effects of luteinizing hormone\u2013releasing hormone agonist therapy on bone health: implications in the management of prostate cancer"],"prefix":"10.1016","volume":"62","author":[{"given":"SAM S","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2003.10.006_BIB1","doi-asserted-by":"crossref","unstructured":"The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79: 235\u2013246, 1997","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x"},{"key":"10.1016\/j.urology.2003.10.006_BIB2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenopathy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med"},{"issue":"suppl 2A","key":"10.1016\/j.urology.2003.10.006_BIB3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)02397-X","article-title":"Side effects of androgen deprivation therapy","volume":"61","author":"Higano","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2003.10.006_BIB4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jc.87.2.599","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB5","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1020840311573","article-title":"Osteoporosis and other adverse body composition changes during androgen deprivation therapy","volume":"21","author":"Smith","year":"2002","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.urology.2003.10.006_BIB7","unstructured":"National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center: Osteoporosis in men. Available at: http:\/\/www.osteo.org\/newfile.asp?doc=r615i&doctitle=Osteoporosis+in+Men&doctype=HTML+Fact+Sheet. Accessed June 30, 2003"},{"key":"10.1016\/j.urology.2003.10.006_BIB8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0895-4356(88)90036-4","article-title":"Lifetime fracture risk","volume":"41","author":"Melton","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urology.2003.10.006_BIB9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s001980050105","article-title":"Lifetime risk of hip fractures is underestimated","volume":"8","author":"Oden","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.urology.2003.10.006_BIB10","unstructured":"World Health Organization: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva, World Health Organization, 1994. WHO Technical Report Series, No. 843."},{"key":"10.1016\/j.urology.2003.10.006_BIB11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/PL00004177","article-title":"Do men and women fracture bones at similar bone densities?","volume":"11","author":"Selby","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.urology.2003.10.006_BIB12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00223-001-1062-6","article-title":"Androgens","volume":"69","author":"Orwoll","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.urology.2003.10.006_BIB13","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1210\/jc.80.12.3689","article-title":"Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens","volume":"80","author":"Morishima","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002239900106","article-title":"Aromatization of androgens is important for skeletal maintenance of aged male rats","volume":"59","author":"Vanderschueren","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.urology.2003.10.006_BIB15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urology.2003.10.006_BIB16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jcem-69-3-523","article-title":"Castrated men exhibit bone loss","volume":"69","author":"Stepan","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1210\/jcem-67-4-701","article-title":"The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism","volume":"67","author":"Johansen","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.76.2.288","article-title":"Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)","volume":"76","author":"Goldray","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB19","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/jc.86.6.2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.urology.2003.10.006_BIB21","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.10967","article-title":"Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2003.10.006_BIB22","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.87.8.3656","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2003.10.006_BIB23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2003.10.006_BIB26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma","volume":"83","author":"Diamond","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2003.10.006_BIB27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2003.10.006_BIB29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2003.10.006_BIB30","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2165\/00002512-200219120-00002","article-title":"Background to and management of treatment-related bone loss in prostate cancer","volume":"19","author":"Berruti","year":"2002","journal-title":"Drugs Aging"},{"issue":"suppl 1","key":"10.1016\/j.urology.2003.10.006_BIB33","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00000421-200212001-00002","article-title":"Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis","volume":"25","author":"Green","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urology.2003.10.006_BIB34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2003.10.006_BIB35","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2003.10.006_BIB36","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2003.10.006_BIB37","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0022-5347(17)36890-8","article-title":"Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates","volume":"148","author":"Sun","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB38","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2003.10.006_BIB39","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2003.10.006_BIB40","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2003.10.006_BIB41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002512-200320030-00002","article-title":"Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2003","journal-title":"Drugs Aging"},{"issue":"suppl 1","key":"10.1016\/j.urology.2003.10.006_BIB42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000052546","article-title":"Treatment of locally advanced prostate cancer","volume":"39","author":"Abrahamsson","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2003.10.006_BIB43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(02)02006-X","article-title":"Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer","volume":"61","author":"Smith","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2003.10.006_BIB44","first-page":"314a","article-title":"Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS)","volume":"18","author":"Higano","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.urology.2003.10.006_BIB45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0305-7372(03)00076-8","article-title":"Management of treatment-related osteoporosis in men with prostate cancer","volume":"29","author":"Smith","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urology.2003.10.006_BIB46","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/01.ju.0000061024.75334.40","article-title":"Transdermal estradiol therapy for advanced prostate cancer","volume":"169","author":"Ockrim","year":"2003","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429503010987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429503010987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T20:25:31Z","timestamp":1550262331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429503010987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S0090429503010987"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2003.10.006","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}